Cost-effectiveness of procalcitonin-guided antibiotic duration for hospitalized patients with sepsis
Authors' conclusion
This economic analysis has shown that a PCT-guided protocol to guide the duration of antibiotic treatment could be cost-effective.
Study context
- Population
- Hospitalised adults with sepsisADAPT-Sepsis trial
- Participants
- 2,760 adults
- Comparison
- Daily procalcitonin (PCT)-guided protocol vs standard care for antibiotic duration
- Outcome
- Incremental costs and QALYs gained, daily PCT-guided protocol vs standard care
Methodological detailscost-effectiveness analysis, trial-based analysis (ADAPT-Sepsis), meta-analysis-based model, lifetime horizon
- Cost-effectiveness analysis
- Trial-based analysis (ADAPT-Sepsis)
- Meta-analysis-based model
- Lifetime horizon
Pooled result
As reported in the abstract
Incremental cost and QALYs (ADAPT-Sepsis)
Incremental cost per patient, PCT vs standard care
€427
Quality-adjusted life year (QALY) loss, PCT vs standard care
0.001
Further pooled results
Incremental cost and QALYs (meta-analysed data, lifetime horizon)
- Incremental cost per patient
- €330
- QALYs gained
- 0.139
- Cost per QALY gained
- €2384
Scenario: only antibiotic use and PCT tests differ
- Incremental cost per patient, no more than
- €110
- QALYs equal in both arms (ADAPT-Sepsis or meta-analysed data)
Original publication
Cost-effectiveness of procalcitonin-guided antibiotic duration for hospitalized patients with sepsis. Crit Care. Published 28 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →